Nasus Pharma Ltd. (NSRX)
NYSE: NSRX · Pharmaceutical Preparations · Tel Aviv - Yafo, IL · filing with the SEC since 2024
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Mar 25, 2026 | · | · | · |
| Revenue | 1,235,000 | · | · | · |
| Research and development | 2,237 | 335 | 567 | · |
| General and administrative | 2,667 | 743 | 580 | · |
| Total operating expenses | 4,904 | 1,078 | 1,147 | · |
| Operating income | -4,904 | -1,078 | -1,147 | · |
| Interest expense | -78 | 29 | 49 | · |
| Interest income (expense), net | -78 | 29 | 49 | · |
| Income from continuing operations | -5,805 | -1,552 | -1,005 | · |
| Income from discontinued operations | -51 | 20 | -46 | · |
| Net income | -5,856 | -1,532 | -1,051 | · |
| Net income to common shareholders | 5,856 | 1,532 | 1,051 | · |
| Earnings per share, basic | -0.72 | -0.22 | -0.15 | · |
| Earnings per share, diluted | -0.72 | -0.22 | -0.20 | · |
| Weighted average shares, basic | 8,010,126 | 7,027,725 | 6,889,708 | · |
| Weighted average shares, diluted | 8,010,126 | 7,027,725 | 7,057,820 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetIncome from continuing operations profit from the businesses it keeps
us-gaap:IncomeLossFromContinuingOperationsIncome from discontinued operations profit or loss from businesses it sold or closed
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding